Author: Macchi M1, Belfiore MP2, Floridi C3, Serra N4, Belfiore G5, Carmignani L6, Grasso RF7, Mazza E8, Pusceddu C9, Brunese L10, Carrafiello G11
Affiliation:
1Department of Radiology, Circolo e Fondazione Macchi Hospital, Insubria University, Varese, Italy.
2Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy.
3Radiology Department, Fatebenefratelli Hospital, Milan, Italy. chiara.floridi@gmail.com.
4Department of Radiology and Radiotherapy, University of Campania "Luigi Vanvitelli", Naples, Italy.
5Department of Radiology, Sant'Anna e San Sebastiano Hospital, Caserta, Italy.
6Interventional Radiology Unit, San Jacopo Hospital, Pistoia, Italy.
7Department of Diagnostic and Interventional Radiology, Campus Bio-Medico University, Rome, Italy.
8Interventional Radiology Unit, Careggi Hospital, Florence, Italy.
9Division of Interventional Radiology, Department of Oncological Radiology, Oncological Hospital "A. Businco", Cagliari, Italy.
10Department of Radiology, University of Molise, Campobasso, Italy.
11Department of Radiology, San Paolo Hospital, University of Milan, Milan, Italy.
Conference/Journal: Med Oncol.
Date published: 2017 May
Other:
Volume ID: 34 , Issue ID: 5 , Pages: 96 , Special Notes: doi: 10.1007/s12032-017-0946-x. Epub 2017 Apr 18. , Word Count: 229
The LUMIRA trial evaluated the effectiveness of radiofrequency (RFA) and microwave ablation (MWA) in lung tumours ablation and defining more precisely their fields of application. It is a controlled prospective multi-centre random trial with 1:1 randomization. Fifty-two patients in stage IV disease (15 females and 37 males, mean age 69 y.o., range 40-87) were included. We randomized the patients in two different subgroups: MWA group and RFA group. For each group, we evaluated the technical and clinical success, the overall survival and complication rate. Inter-group difference was compared using Chi-square test or Fisher's exact test for categorical variables and one-way ANOVA test for continuous variables. For RFA group, there was a significant reduction in tumour size only between 6 and 12 months (p value = 0.0014). For MWA group, there was a significant reduction in tumour size between 6 and 12 months (p value = 0.0003) and between pre-therapy and 12 months (p value = 0.0215). There were not significant differences between the two groups in terms of survival time (p value = 0.883), while the pain level in MWA group was significantly less than in RFA group (1.79 < 3.25, p value = 0.0043). In conclusion, our trial confirms RFA and MWA are both excellent choices in terms of efficacy and safety in lung tumour treatments. However, when compared to RFA therapy, MWA produced a less intraprocedural pain and a significant reduction in tumour mass.
KEYWORDS: Ablation treatment; Lung cancer; Microwave; Radiofrequency
PMID: 28417355 DOI: 10.1007/s12032-017-0946-x
